YH003
2021.01.12
Drug : YH003(CD40)
Progress : Phase I/II clinical trial
Indication : Phase I for solid tumor; Phase II for melanoma, and pancreatic cancer
Country/Region : Australia
Study Title : A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in combination with Toripalimab (anti-PD-1 mAb) in Subjects with Advanced Solid TumorsLink to Trial : https://clinicaltrials.gov/ct2/show/NCT04481009
More information
Eucure (Beijing) Biopharma Co., Ltd.
23F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, P. R. China,100025
WeChat
2020 Eucure & Biocytogen京ICP备18006768号-1